GW pilot study finds collagen to be effective in wound closure

July 08, 2019

WASHINGTON (July 8, 2019) -- Collagen powder is just as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures, according to a first-of-its-kind study published in the Journal of Drugs in Dermatology by a team of physician researchers at the George Washington University.

The team investigated the efficacy of topical collagen powder compared to primary closure on the rate and quality of full-thickness wound healing through histopathological analysis of healing and comparison of symptoms and early cosmetic outcomes.

Collagen is best known as an essential structural component of several organs, importantly the skin, but it also plays a pivotal role as a signaling molecule in the regulation of all phases of wound healing. Therefore, externally applied, collagen powder has significant potential for wound healing and care due to its ability to stop bleeding, to recruit immune and skin cells central to wound healing, as well as stimulate new blood vessel formation, and can be left in wounds without causing irritation or facilitating bacterial growth.

"During normal wound healing, collagen acts as a scaffold for cellular entry and growth in the wound bed and encourages the deposition of new collagen," said Adam Friedman, MD, interim chair of the Department of Dermatology at the GW School of Medicine and Health Sciences and an author on the study. "While collagen has been used as a wound healing adjuvant, a good comparison to the standard of wound care has been lacking."

Friedman's team administered two punch biopsies to eight volunteers and treated one wound with a daily topical collagen powder and the other with primary closure. Wounds were biopsied at four weeks for analysis and subjects were asked to rate the itch, pain, and treatment preferences throughout the process.

The researchers found that six out of eight collagen-treated wounds were completely healed after four weeks after initial wounding and all wounds were completely healed eight weeks after the second biopsy. Patients reported similar pain and itch for both primary closure and collagen, with most attributing the itch to the adhesive dressings rather than the wound itself. The team concluded that based on these findings, wounds treated with collagen powder healed at least as well as those treated with primary closure and that the powder can be applied safely for at least four weeks.

"Given the cost and time to place and remove sutures and the potential reimbursement for collagen, using topical collagen powder for punch biopsy wounds may be easier on the patient, not requiring an additional visit for suture removal and yielding an equivalent or possibly better wound healing outcome," Friedman said. "Moving forward we need to further examine the parameters of collagen use on wounds, including duration of therapy and wound sizes."
-end-
The study, titled "A Head-to-Head Comparison of Topical Collagen Powder to Primary Closure for Acute Full-Thickness Punch Biopsy-Induced Human Wounds: An Internally Controlled Pilot Study," is published in the Journal of Drugs in Dermatology.

George Washington University

Related Biopsy Articles from Brightsurf:

Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
Building on previous research led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published in Nature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA), allows for the more precise characterization, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumor in childhood.

Liquid biopsy faster than tissue biopsy, improves time to treat
A pilot study comparing the effects of a liquid biopsy with tissue-based test showed that liquid biopsy turn-around time for results was approximately 10 days faster than the tissue biopsy, according to research presented today at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference.

Study focuses on a different kind of liquid biopsy to detect cancer
In a study published August 13, 2020, in Cell by a team of collaborators from Memorial Sloan Kettering and Weill Cornell Medicine, researchers report that tiny packages of materials released by tumors, called EVPs (extracellular vesicles and particles), may serve as biomarkers for detecting a number of different types of cancer in the early stages.

Chip for liquid biopsy will help to detect prostate cancer
Researchers of Sechenov University together with their colleagues from Australia used the microfluidics technology to develop a device able to isolate cancer cells from urine of patients with prostate cancer.

Hybrid microscope could bring digital biopsy to the clinic
By adding infrared capability to the ubiquitous, standard optical microscope, researchers at the University of Illinois at Urbana-Champaign hope to bring cancer diagnosis into the digital era.

Sentinel lymph node biopsy has no benefits for stage zero breast cancer
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.

CNIO researchers assess melanoma progression with a new liquid biopsy technique
Analysis of extracellular vesicles and circulating DNA from fluid obtained from the drainage implanted after surgery, normally disposed of as medical waste, detects melanoma patients with risk of recurrence and may help doctors decide who should undergo adjuvant therapy The new technique might change the way melanoma patients are followed up.

Contrast-enhanced MRI provides useful findings in discordant core biopsy management
An essential part of breast intervention is the process of assessing concordance between imaging findings and core biopsy results.

3D mammography significantly reduces breast biopsy rates
The use of digital breast tomosynthesis, also known as 3D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study.

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy.

Read More: Biopsy News and Biopsy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.